The Effect of Probiotics on Gut Microbiota during the <i>Helicobacter pylori</i> Eradication: Randomized Controlled Trial

Oh, Bumjo; Kim, Bong Soo; Kim, Ji Won; Kim, Jong Seung; Koh, Seong‐Joon; Kim, Byeong Gwan; Lee, Kook Lae; Chun, Jongsik

doi:10.1111/hel.12270

Cited by 142 publications

(168 citation statements)

References 39 publications

Supporting

Mentioning

158

Contrasting

Order By: Relevance

“…Then, in a study exploring both short-and long-term effects of H. pylori therapy, it has been demonstrated that although the diversity of the microbiota subsequently recovered to resemble the pre treatment states, the microbiota remained perturbed in some cases for up to 4 years post treatment [91]. More recently, as it evidenced by Chun J et al [93], probiotic supplementation can reduce the antibiotic-induced alteration and imbalance of the gut microbiota composition. More recently, as it evidenced by Chun J et al [93], probiotic supplementation can reduce the antibiotic-induced alteration and imbalance of the gut microbiota composition.…”

Section: H Pylori Eradication and The Alterations Of Microbiotamentioning

confidence: 99%

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

Yang

Lü

2016

Helicobacter

View full text Add to dashboard Cite

The development of new nucleotide sequencing techniques and advanced bioinformatics tools has opened the field for studying the diversity and complexity of the gastrointestinal microbiome independent of traditional cultural methods. Owing largely to the gastric acid barrier, the human stomach was long thought to be sterile. The discovery of Helicobacter pylori, the gram-negative bacterium that infects upwards of 50% of the global population, has started a major paradigm shift in our understanding of the stomach as an ecologic niche for bacteria. Recent sequencing analysis of gastric microbiota showed that H. pylori was not alone and the interaction of H. pylori with those microorganisms might play a part in H. pylori-associated diseases such as gastric cancer. In this review, we summarize the available literature about the changes of gastrointestinal microbiota after H. pylori infection in humans and animal models, and discuss the possible underlying mechanisms including the alterations of the gastric environment, the secretion of hormones and the degree of inflammatory response. In general, information regarding the composition and function of gastrointestinal microbiome is still in its infancy, future studies are needed to elucidate whether and to what extent H. pylori infection perturbs the established microbiota. It is assumed that clarifying the role of gastrointestinal communities in H. pylori-associated diseases will provide an opportunity for translational application as a biomarker for the risk of serious H. pylori diseases and perhaps identify specific organisms for therapeutic eradication.

show abstract

Section: H Pylori Eradication and The Alterations Of Microbiotamentioning

confidence: 99%

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

Yang

Lü

2016

Helicobacter

View full text Add to dashboard Cite

show abstract

“…[76][77][78][79] Bismuth-based quadruple therapy was used in two studies. [76][77][78][79][80][81] Shortly after H pylori eradication therapy, the bacterial diversity was significantly reduced at the end of eradication therapy. [76][77][78][79][80][81] Shortly after H pylori eradication therapy, the bacterial diversity was significantly reduced at the end of eradication therapy.…”

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

“…80,81 The case numbers are relatively small, ranging from 6 to 70, with a total of 147 cases. [76][77][78][79][80][81] In patients treated with triple therapy, the relative abundance of Firmicutes was reduced, whereas that of Proteobacteria was increased. [76][77][78][79][80][81] In patients treated with triple therapy, the relative abundance of Firmicutes was reduced, whereas that of Proteobacteria was increased.…”

Section: Impac T Of H Pylori Er Adic Ation On G Ut MI Crob I Otamentioning

confidence: 99%

Review: Treatment of Helicobacter pylori Infection 2019

et al. 2019

View full text Add to dashboard Cite

This review summarizes important studies regarding Helicobacter pylori therapy published from May 2018 to May 2019. The main themes that emerge involve studies assessing the efficacy of bismuth‐based regimens. While in recent years the efficacy of bismuth‐based quadruple therapy as a second‐line therapy has been clearly established, there is now substantial evidence that it is the best performing first‐line therapy. Antibiotic resistance was again intensely studied this year, and a clear and dramatic increase in resistance is noted for clarithromycin and levofloxacin; most notably, it may not be possible to support these therapies in most regions of the world much longer without testing. The utility of vonoprazan as an alternative to proton‐pump inhibitor therapy, especially in resistant and difficult to treat groups, has also been considered in greater detail this year, as well as means of supporting and enhancing adherence to therapy. Several studies showed that the diversity of gut microbiota was significantly altered shortly after H pylori eradication. However, the diversity was restored to pre‐treatment state after 2 months in patients treated with triple therapy. More studies are warranted to assess the long‐term changes of gut microbiota after H pylori eradication.

show abstract

“…Additionally, Emara et al focused on the emerging role of Pbs from a histopathological perspective and found that Pbs lowered H. pylori density on the luminal side of the epithelium, thereby improving the histological inflammatory and activity scores in the gastric corpus and antrum over an extended period (Emara et al, 2016). Moreover, H. pylori eradication influenced the gut microbiota (Jakobsson et al, 2010; Malfertheiner et al, 2016); the addition of Pbs (e.g., Streptococcus faecium and Bacillus subtilis ) to standard triple therapies may restrict the growth of antibiotic-resistant bacteria and reduce the fluctuation of the gut microbiota (Oh et al, 2016). …”

Section: Treatmentmentioning

confidence: 99%

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Zhu

Lü

2017

Front. Cell. Infect. Microbiol.

134

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments. A PubMed literature search was performed using the following keywords: Helicobacter pylori, infection, reinfection, antibiotic resistance, bismuth, proton pump inhibitors, vonoprazan, susceptibility, quintuple therapy, dual therapy, and probiotic. The prevalence of H. pylori has remained high in some areas despite the decreasing trend of H. pylori prevalence observed over time. Additionally, the H. pylori reinfection rate has varied in different countries due to socioeconomic and hygienic conditions. Helicobacter pylori monoresistance to clarithromycin, metronidazole or levofloxacin was common in most countries. However, the prevalence of amoxicillin and tetracycline resistance has remained low. Because H. pylori infection and reinfection present serious challenges and because H. pylori resistance to clarithromycin, metronidazole or levofloxacin remains high in most countries, the selection of an efficient regimen to eradicate H. pylori is critical. Currently, bismuth-containing quadruple therapies still achieve high eradication rates. Moreover, susceptibility-based therapies are alternatives because they may avoid the use of unnecessary antibiotics. Novel regimens, e.g., vonoprazan-containing triple therapies, quintuple therapies, high-dose dual therapies, and standard triple therapies with probiotics, require further studies concerning their efficiency and safety for treating H. pylori.

show abstract

The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial

Abstract: Probiotic supplementation can reduce the antibiotic-induced alteration and imbalance of the gut microbiota composition. This effect may restrict the growth of antibiotic-resistant bacteria in the gut and improve the H. pylori eradication success rate.

Cited by 142 publications

References 39 publications

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

Imbalance of Gastrointestinal Microbiota in the Pathogenesis ofHelicobacter pylori‐Associated Diseases

Review: Treatment of Helicobacter pylori Infection 2019

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Contact Info

Product

Resources

About